Verona Pharma PLC Services Agreement with QuintilesIMS (1503A)
March 22 2017 - 3:01AM
UK Regulatory
TIDMVRP
RNS Number : 1503A
Verona Pharma PLC
22 March 2017
Verona Pharma Enters Global Strategic Clinical Development
Services Agreement with QuintilesIMS for RPL554
Establishes research and operational platform for clinical
trials covering COPD and Cystic Fibrosis
22 March 2017, London - Verona Pharma plc (AIM: VRP.L) (Verona
Pharma), a clinical-stage biopharmaceutical company focused on
developing and commercialising innovative therapeutics for the
treatment of respiratory diseases with significant unmet medical
needs, today announced it has entered into a global strategic
services agreement with QuintilesIMS, a leading provider of
biopharmaceutical development and commercial outsourcing
services.
The services agreement establishes an operational platform to
facilitate Verona Pharma's global clinical trial-related activities
for the development of its product candidate RPL554 for the
treatment of COPD (chronic obstructive pulmonary disease) and
cystic fibrosis and for future commercialisation initiatives.
Pursuant to the agreement, Quintiles will serve as sole provider
of core clinical trial services for Verona Pharma's RPL554 clinical
development programs. Verona Pharma will have full access to
Quintiles' therapeutic and operational experts throughout the
duration of each trial, from the planning and design through to
execution. Joint governance and quality oversight has been
established to ensure strategic and operational goals are met and
compliance with regulatory and quality requirements. Verona Pharma
will also have access to QuintilesIMS' global commercial insights
when developing its market access strategy in the United States for
RPL554.
Verona Pharma's product candidate, RPL554, is an inhaled, dual
PDE3/PDE4 inhibitor that acts as both a bronchodilator and an
anti-inflammatory agent in a single compound. Verona Pharma is
currently developing RPL554 for the maintenance treatment of COPD
patients and as an add-on therapy to commonly used therapies for
the treatment of hospitalized patients with acute exacerbations of
COPD. It is also developing RPL554 for the treatment of patients
with cystic fibrosis.
Dr Jan-Anders Karlsson, Verona Pharma's Chief Executive Officer,
commented, "Verona Pharma is focused on advancing the clinical
development of RPL554 for the treatment of COPD and cystic
fibrosis. The Company has already completed eight Phase 1 and 2a
clinical trials for RPL554, and we believe that our strategic
services agreement with QuintilesIMS will enhance the agility,
productivity and commercial viability of our development activities
as we progress multiple larger and later stage clinical
trials."
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company
focused on developing and commercialising innovative therapeutics
for the treatment of respiratory diseases with significant unmet
medical needs.
Verona Pharma's product candidate, RPL554, is a first-in-class,
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4
that acts as both a bronchodilator and an anti--inflammatory agent
in a single compound. In clinical trials, treatment with RPL554 has
been observed to result in statistically significant improvements
in lung function as compared to placebo and has shown clinically
meaningful and statistically significant improvements in lung
function when added to two commonly used bronchodilators as
compared to either bronchodilator administered as a single agent.
Verona Pharma is developing RPL554 for the treatment of chronic
obstructive pulmonary disease (COPD), cystic fibrosis, and
potentially asthma.
Forward Looking Statements
This press release contains forward-looking statements. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements.
These forward-looking statements are based on management's
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from our
expectations expressed or implied by the forward-looking
statements, including, but not limited to, the provision of
clinical trial and other services by QuintilesIMS and the potential
value of such services to our development activities.
These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management's estimates as of the date of this
press release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283
4200
Jan-Anders Karlsson, Chief Executive info@veronapharma.com
Officer
N+1 Singer (Nominated Adviser Tel: +44 (0)20 7496
and UK Broker) 3000
Aubrey Powell / James White
FTI Consulting (UK Media and Tel: +44 (0)20 3727
Investor enquiries) 1000
Simon Conway / Stephanie Cuthbert veronapharma@fticonsulting.com
/
Natalie Garland-Collins
ICR, Inc. (US Media and Investor
enquiries)
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRSEWEDFFWSEID
(END) Dow Jones Newswires
March 22, 2017 03:01 ET (07:01 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
